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Palliative care in cancer patients 
In palliative care- the holistic care of patients with advanced 
disease- managing pain and other symptoms is crucial. This article 
describes a study aimed at developing pharmacist intervention 
within a local provider's care programme 
P alliative care, as defined by the World Health Organization (WHO), is an approach that improves the quality of life of patients and their 
families when fac1ng the problems of end-stage dis-
ease, via prevention and relief of suffering by means 
of early identification and impeccable assessment 
and treatment of pain and other problems, physical, 
psychosocial and spiritual.' 
Interventions made by a hospice pharmacist include 
dispensing medications. educating patients and their 
families, identifying drug-therapy problems. recom-
mending drug therapies and developing protocols.2 In 
Malta there is no hospice pharmacist within the multi-
disciplinary team providing palliative care. This study 
aimed to develop and evaluate pharmacist interven-
tion in palliative care with respect to pain and symp-
tom management and develop a pharmaceutical care 
plan for patients receiving palliative care. The results 
should therefore provide a framework for developing a 
system usable by pharmacists providing this serv1ce. 
Methodology 
This study was carried out at the Malta Hospice Move-
ment centre in Malta. The organisation provides and 
promotes palliative care for people with end-stage 
disease and supports their fami lies.3 Sixteen patients 
were randomly selected and visited at home by the 
investigator and hospice nurse. During the first visit 
the investigator (MP) performed several interventions. 
The impact of these was evaluated during the second 
visit. Documentation tools were developed and used to 
estimate compliance and quality of life as parameters 
to evaluate impact of pharmacist interventions. Each 
patient was reassured that the interview consisted of 
a number of questions concerning their pharmacologi-
cal treatment and quality of life and included no form 
of physical examination. 
Patients included in the study were either newly 
diagnosed with cancer or in relapse. All patients 
recruited were assigned an identification number 
known only to the investigator. 
During t he first visit patients were given a drug doc-
umentation sheet prepared by the investigator. to pro-
vide a detailed description of the drug regimen, in the 
form of a card completed during the visit. The design 
was intended to be easy for patients to follow. s1nce 
they could refer to it to check when medications were 
due.• The investigator completed a pharmacist docu-
mentation sheet detailing tasks undertaken during the 
visit. All potential pharmacist interventions observed 
were noted and incorporated into the latter sheet. In 
this way, the time taken to document interventions 
necessary during the visit was kept limited. 
The investigator compiled a pharmaceutical care 
plan (PCP) for each patient, including data such as 
the pat ient's medical history, current drug therapy 
(prescription-only and nonprescript ion medications) 
and a monitoring plan. The PCP involves assessing 
patient's health problems and needs, setting objec-
tives. performing interventions and evaluating results. 
Its development can be summarised as a five-step 
process based on the SOAP format (Subjective data, 
Objective data, Assessment. Plan of care).5 
It is important to have a valid, reliable means of 
measuring quality of life in patients w ith end-stage 
disease since quality-of-life improvement is the reason 
for every intervention in palliative care. Patients were 
asked to complete the McGill Quality of Life (MQOL) 
Questionnaire6 and a Compliance Questionnaire.7 The 
MQOL is a multidimensional document relevant to all 
phases of the disease course for such patients;6 the 
other questionnaire was used to assess compliance 
among cancer patients.7 Both questionnaires com-
prise close-ended questions. with the MQOL using a 
Likert scale as a type of psychometric response scale 
and the Compliance Questionnaire using a combina-
tion of three close-ended question styles (multiple-
choice. categorical, numerical). Respondents then 
specified their level of agreement with statements 
proposed. 
The second visit took place four weeks later. Since 
the first visit three patients had died, so 13 patients 
participated in both visits. The drug documentation 
sheet and pharmaceutical care plan were reviewed 
and amended according to changes deemed neces-
sary by the physician and/or oncologist. Patients were 
asked to complete the MQOL and compliance ques-
tionnaires again to assess any differences in quality of 
life and ascertain that the patient was compliant with 
all medications. 
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Figure 1. Physical 
symptoms in the last 
two days accord ing 
to the McGill Quality 
of Life Questionnaire 
at visit one and visit 
two (n= 13) 
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Data analysis of life. There was no statistically significant difference 
The data was analysed using SPSS® Version 14.0. The between psychological symptoms (p=0.121) and 
paired sample t-test was the parametric test used to support (p=0.418) domains. 
establish whether a statist ical significant difference 
resulted between visits one and two. 
Results 
Descriptive statistics 
The mean and median ages of the patients were 68.8 
and 70 years respectively (range 53 86 years). Four 
(31 %) patients were male and nine (69%) female. 
Medications missed 
The mean number of medications prescribed or 
taken at visit one was 7. 77, of which 4.38 were can-
cer-related. During the first visit eight patients (62%) 
said they were noncompliant at times. The investiga-
tor spent some time on patient education with these 
individuals, highlighting the importance of compliance 
and explaining that the medications prescribed would 
Physical symptoms contribute to a better quality of life. At the second 
Patients were asked to note three physical symp- visit, the number of patients who said they missed a 
toms from which they suffered most. At visit one, dose had decreased to three (23%). 
seven (54%) pat ients complained of loss of appetite, 
compared with four (31 %) at visit two, while weak- Compliance issues 
ness and pain were reported by seven (54%) and six Of the noncompliant patients at visit one, three (38%) 
(46%) patients respectively as the most troublesome did not comply since they claimed to be asympto-
symptoms in both visits. Figure 1 highlights the most mat ic, two (25%) experienced side-effects, one (12%) 
troublesome symptoms experienced by patients as showed lack of concern and another two (25%) admit-
observed in the MOOL questionnaire. ted they forgot to take their scheduled dosage. When 
patients were asked what they did when they missed 
MQOL domains a dose, six (75%) admitted to skipping the dose alto-
The MOOL questionnaire consists of 17 questions gether and two (25%) taking the medication when 
and is divided into five quality-of-life domains: physical they remembered. Asked whether they were com-
symptoms, physical wellbeing, psychological symp- pliant with the prescribed times of their medication. 
toms, existential wellbeing and support. However, four (31 %) answered in the negative, but no patient 
for data analysis the single-item measure of physical interviewed at visit two reported doing so. 
wellbeing was considered together with the psycho-
logical symptoms domain. 
There was a statistically significant improve-
ment (p=0.025) in the patients' physical well-being 
between visits one and two. The rating score shifted 
to the right with higher scores, indicating a better 
state of physical wel lbeing. There was a statistically 
significant improvement (p=0.001) in the existential 
wellbeing section, with a shift to the right indicating 
better social status. A statistically significant improve-
ment (p=0.018) was also achieved in overall quality 
Pharmacist intervention 
Before starting any interventions during visit one, the 
pharmacist asked the patients whether they thought it 
would be beneficial to have a pharmacist as part of the 
multidisciplinary team. Only two (15%) patients said a 
pharmacist would be beneficial and would contribute 
significantly to the patient's quality of life. At visit two, 
after patients had been subjected to pharmacist inter-
ventions, they were asked the question again. The 
number of patients admitting that a pharmacist would 
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indeed be beneficial within the team increased to 10 
(77%). Figure 2 il lustrates pharmacist interventions 
during the visits, the most prominent being documen-
tation, educating patients and checking compliance in 
100% of cases and identifying drug-related problems 
in 77% of cases. The investigator was responsible for 
documentation by completing the drug and pharma-
cist documentation sheets and the pharmaceutical 
care plan for all patients. Other pharmacist responsi-
bilities included educating patients and staff regard-
ing side-effect and drug-interaction profile, method 
of administration, dosing frequency, any precautions 
and other general advice, and checking compliance 
through patient interviews. 
Prescribing trends 
Figure 3 shows the frequency of local prescribing 
trends in palliative care. The drugs in the "other" cat-
egory included etoricoxib, paroxetine and ranitidine 
prescribed once, and amitriptyline, diazepam, esome-
prazole, indomethacin, meloxicam, nortriptyline and 
zolpidem, each of these being prescribed twice. 
Documentation sheets 
At visit two the drug documentation sheet was 
amended according to the medications being taken 
as prescribed by the physicians. Eight patients (62%) 
had their sheet amended due to a change in medi-
cation, be it cancer-related or not. Pharmacological 
therapy in cancer patients is ever-changing, so it was 
of paramount importance for the documentation 
sheet to be updated so patients would continue to 
follow the correct drug schedule. The pharmaceuti-
ca l care plan was also fol lowed up at visit two. Treat-
ment goals were reviewed and changed depending 
on circumstances. 
Discussion 
The results tor the physical and existential wellbeing 
and overall quality-of-life sections of the MOOL at visit 
one differed significantly f rom those obtained after 
pharmacist intervention at visit two. Furthermore, if 
the mean rating scores were not significantly differ-
ent one could argue that there was either no associa-
tion between visits, so all results were attributable to 
chance. or there was an association but the sample 
size was too smal l to be recognised. 
Results showed that compliance with medication 
improved at visit two, after the pharmacist interven-
tion, and this could be attributed to two factors: the 
pharmacist's role in educating the patients and their 
famil ies, and the distribution of the drug documen-
tation sheet. Patients education measures included 
general advice along with explanations of the side-
effect and interaction profile, method of administra-
• 1. Documentation. educating patients, 
checking compliance 
2. Identifying problems 
• 3. Educating staff, recommending drug 
therapies 
• 4. Monitoring therapeutic outcomes 
• 5. Identifying drugs, assessing 
problems, referring patient. contacting 
physician 
• 6. Labeling drugs, recommendat ions for 
adequate control. councelling patients 
• 7. Explanation of how devices are used 
8. Optimising expenditures 
Figure 2. Pharmacist interventions during the visits (n=13) 
tion, dosing frequency, and precautions for use. This 
was successful, as indicated by patient feedback. 
The distribution of the drug documentation sheet 
impacted positively on cancer patients, helping to 
improve their compliance with medication. 
The number of patients saying they took medi-
cation at the prescribed times increased after the 
pharmacist intervention, again indicating that such 
intervention, be it in the form of patient educa-
tion or distribution of memory aids in the form of a 
documentation sheet, was indeed successful. 
The visit by the pharmac1st was effective, as 
demonstrated by the change in patients' perception. 
When patients were asked what they found most 
useful, the majority (n=10, 77%) mentioned the drug 
documentation sheet, saying this made it easier for 
them to follow the physician's instructions. Others 
(38%) mentioned the pharmacist's role in explaining 
use of particular devices, such as the syringe driver. 
Almost all patients gave positive feedback on the fact 
that the pharmacist spent quality time with them and 
offered individual attention. The presence of a phar-
macist was well received by the hospice staff, who 
agreed that having a pharmacist on the team would 
greatly improve patient care. 
One of the limitations of the study was that 
patients were interviewed twice with a gap of only 
four weeks between interviews. Had the time inter-
val been longer another visit could have been made, 
providing a more holistic picture of the patient. How-
ever, too long an interval would have made the prob-
ability of deaths more likely. The difference in interval 
is significant since quality of life changes constantly 
with time or disease progression .a As documented by 
Lo et al, quality of life becomes progressively worse 
as death becomes more imminent.9 
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Figure 3 . Palliative care prescribing trends in Malta (n=13) 
Conclusion 
There is currently no hospice pharmacist in the local 
scenario. This study has shown that involving a phar· 
macist in the care provided by a hospice results in a 
better quality of life and increased medication compli-
ance in cancer patients. Patients valued the presence 
of a pharmacist within the team. The duties of such a 
pharmacist vary widely and can be executed in a tailor-
made way by a pharmacist to complement the work 
of the holistic team. A multidisciplinary team approach 
would be more complete if the team included a hos-
pice pharmacist actively involved in implementing 
palliative care services. • 
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